The next two to three years will see important changes in the coordination of the drug monitoring systems of the European Union (EU) and in the role played by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in supporting research and science-based responses at the national level. The European Commission has presented a legislative proposal to revise the mandate of the EMCDDA to ensure that the agency is prepared to meet future challenges of the drugs phenomenon.